HUE052904T2 - Imidazolin-származékok, azok elõállítási módszerei és alkalmazásuk az orvostudományban - Google Patents

Imidazolin-származékok, azok elõállítási módszerei és alkalmazásuk az orvostudományban

Info

Publication number
HUE052904T2
HUE052904T2 HUE13835193A HUE13835193A HUE052904T2 HU E052904 T2 HUE052904 T2 HU E052904T2 HU E13835193 A HUE13835193 A HU E13835193A HU E13835193 A HUE13835193 A HU E13835193A HU E052904 T2 HUE052904 T2 HU E052904T2
Authority
HU
Hungary
Prior art keywords
medicine
applications
preparation methods
imidazoline derivatives
imidazoline
Prior art date
Application number
HUE13835193A
Other languages
English (en)
Inventor
Hejun Lu
Piaoyang Sun
Hongbo Fei
Hongjian Jiang
Haowei Wang
Qing Dong
Original Assignee
Shanghai hengrui pharmaceutical co ltd
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai hengrui pharmaceutical co ltd, Jiangsu Hengrui Medicine Co filed Critical Shanghai hengrui pharmaceutical co ltd
Publication of HUE052904T2 publication Critical patent/HUE052904T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
HUE13835193A 2012-09-04 2013-08-26 Imidazolin-származékok, azok elõállítási módszerei és alkalmazásuk az orvostudományban HUE052904T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201210323870 2012-09-04

Publications (1)

Publication Number Publication Date
HUE052904T2 true HUE052904T2 (hu) 2021-05-28

Family

ID=50236528

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13835193A HUE052904T2 (hu) 2012-09-04 2013-08-26 Imidazolin-származékok, azok elõállítási módszerei és alkalmazásuk az orvostudományban

Country Status (22)

Country Link
US (2) US9586947B2 (hu)
EP (1) EP2894151B1 (hu)
JP (1) JP6262733B2 (hu)
KR (1) KR102189940B1 (hu)
CN (1) CN103958480B (hu)
AU (1) AU2013312587B2 (hu)
BR (1) BR112015004637B1 (hu)
CA (1) CA2883545C (hu)
CY (1) CY1123649T1 (hu)
DK (1) DK2894151T3 (hu)
ES (1) ES2835248T3 (hu)
HK (1) HK1198476A1 (hu)
HR (1) HRP20202050T1 (hu)
HU (1) HUE052904T2 (hu)
LT (1) LT2894151T (hu)
MX (1) MX368844B (hu)
PT (1) PT2894151T (hu)
RS (1) RS61242B1 (hu)
RU (1) RU2639145C2 (hu)
SI (1) SI2894151T1 (hu)
TW (1) TWI617546B (hu)
WO (1) WO2014036897A1 (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015004637B1 (pt) * 2012-09-04 2022-04-05 Shanghai Hengrui Pharmaceutical Co., Ltd. Derivados de imidazolina, seus usos e seus processos de preparação, e composição farmacêutica
KR20230119040A (ko) * 2015-01-20 2023-08-14 아비나스 오퍼레이션스, 인코포레이티드 안드로겐 수용체의 표적화된 분해를 위한 화합물 및방법
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
WO2017011590A1 (en) * 2015-07-13 2017-01-19 Arvinas, Inc. Alanine-based modulators of proteolysis and associated methods of use
CN106518773A (zh) * 2015-09-10 2017-03-22 江苏恒瑞医药股份有限公司 一种雄性激素受体抑制剂的结晶形式及其制备方法
WO2017041622A1 (zh) 2015-09-10 2017-03-16 江苏恒瑞医药股份有限公司 一种雄性激素受体抑制剂的结晶形式及其制备方法
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
US9963433B2 (en) * 2016-01-29 2018-05-08 Wayne State University Anticancer drugs including the chemical structures of an androgen receptor ligand and a histone deacetylase inhibitor
CN107530325B (zh) 2016-02-19 2021-02-23 江苏恒瑞医药股份有限公司 一种含有咪唑啉类衍生物的药物组合物
EP3481394A1 (en) * 2016-07-08 2019-05-15 Janssen Pharmaceutica N.V. Thiohydantoin androgen receptor antagonists for the treatment of cancer
EP3481813A1 (en) * 2016-07-08 2019-05-15 Janssen Pharmaceutica N.V. Substituted hydantoin and thiohydantoin derivatives as androgen receptor antagonists
RU2733950C1 (ru) * 2017-02-13 2020-10-08 Канпу Биофармасьютикалс, Лтд. Комбинация для лечения рака предстательной железы, фармацевтическая композиция и способ лечения
CN109912509B (zh) * 2017-12-13 2021-02-26 江苏恒瑞医药股份有限公司 一种雄性激素受体抑制剂的晶型及其制备方法
CN110684046B (zh) * 2018-07-06 2023-05-12 江苏恒瑞医药股份有限公司 一种新的咪唑啉类衍生物的制备方法
CN108976171B (zh) * 2018-08-27 2020-06-16 长沙泽达医药科技有限公司 化合物、组合物及其在药物制备中的用途
US11459340B2 (en) 2018-09-18 2022-10-04 Nikang Therapeutics, Inc. Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitors
WO2020083187A1 (zh) * 2018-10-22 2020-04-30 江苏恒瑞医药股份有限公司 一种ar拮抗剂联合parp抑制剂在制备治疗***癌的药物中的用途
BR112021011968A2 (pt) * 2018-12-19 2021-09-08 Celgene Corporation Compostos de 3-((3-aminofenil)amino)piperidina-2,6-diona substituídos, composições dos mesmos e métodos de tratamento com os mesmos
WO2020132016A1 (en) 2018-12-19 2020-06-25 Celgene Corporation Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
GB201908511D0 (en) 2019-06-13 2019-07-31 Adorx Therapeutics Ltd Hydroxamate compounds
CN113929628A (zh) * 2020-06-29 2022-01-14 江苏恒瑞医药股份有限公司 一种咪唑啉衍生物的制备方法
CN113024513A (zh) * 2021-03-22 2021-06-25 中国药科大学 新型雄激素受体降解剂、制备方法和医药用途
CN115850186B (zh) * 2023-02-07 2024-04-09 长沙泽达医药科技有限公司 一种乙撑硫脲衍生物的晶型及用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
EP1466898A4 (en) 2001-12-27 2005-12-07 Daiichi Seiyaku Co INHIBITORS OF THE PRODUCTION / SEPARATION OF BETA-AMYLOIDS PROTEINS
US20060025589A1 (en) * 2002-10-01 2006-02-02 Jean Binet 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes
TW200621723A (en) * 2004-09-09 2006-07-01 Chugai Pharmaceutical Co Ltd Novel imidazolidine derivative and use thereof
US20070015782A1 (en) 2005-04-15 2007-01-18 Eisai Co., Ltd. Benzimidazole compound
US7709517B2 (en) * 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
KR101169832B1 (ko) * 2005-05-13 2012-07-30 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴히단토인 화합물
RS52307B (en) 2006-06-27 2012-12-31 Takeda Pharmaceutical Company Limited CONDENSED CYCLIC UNITS
SG172986A1 (en) 2009-02-10 2011-08-29 Astrazeneca Ab Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
CN101817787B (zh) 2009-02-26 2013-07-24 童友之 抗***癌的雄性激素受体拮抗剂
WO2010118354A1 (en) * 2009-04-09 2010-10-14 Medivation Prostate Therapeutics, Inc. Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods for use thereof
WO2011008543A2 (en) 2009-06-29 2011-01-20 University Of Delaware Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal
JP2013505295A (ja) 2009-09-22 2013-02-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を選択的に調節する化合物
AU2011218167B2 (en) 2010-02-17 2014-07-10 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
RU2434851C1 (ru) 2010-07-22 2011-11-27 Александр Васильевич Иващенко Циклические n, n'-диарилтиомочевины или n, n'-диарилмочевины - антагонисты андрогенных рецепторов, противораковое средство, способ получения и применения
EP2598481B1 (en) 2010-07-26 2016-08-31 Bristol-Myers Squibb Company Sulfonamide compounds useful as cyp17 inhibitors
US9139565B2 (en) * 2010-09-28 2015-09-22 Georgia Tech Research Corporation Histone deacetylase (HDAC) inhibitors targeting prostate tumors and methods of making and using thereof
MX343905B (es) 2010-11-03 2016-11-28 Dow Agrosciences Llc Composiciones pesticidas y procesos relacionados a las mismas.
CN103608333B (zh) * 2011-03-10 2016-01-06 苏州开拓药业有限公司 雄激素受体拮抗剂及其用途
BR112015004637B1 (pt) * 2012-09-04 2022-04-05 Shanghai Hengrui Pharmaceutical Co., Ltd. Derivados de imidazolina, seus usos e seus processos de preparação, e composição farmacêutica

Also Published As

Publication number Publication date
EP2894151A1 (en) 2015-07-15
AU2013312587B2 (en) 2017-03-16
CA2883545C (en) 2020-07-07
EP2894151B1 (en) 2020-11-11
SI2894151T1 (sl) 2021-01-29
HRP20202050T1 (hr) 2021-02-19
PT2894151T (pt) 2020-12-07
WO2014036897A1 (zh) 2014-03-13
TWI617546B (zh) 2018-03-11
CA2883545A1 (en) 2014-03-13
BR112015004637A2 (pt) 2017-07-04
ES2835248T3 (es) 2021-06-22
CN103958480B (zh) 2016-04-06
CY1123649T1 (el) 2022-03-24
TW201410655A (zh) 2014-03-16
BR112015004637B1 (pt) 2022-04-05
US20150225381A1 (en) 2015-08-13
US9895355B2 (en) 2018-02-20
US9586947B2 (en) 2017-03-07
JP2015526487A (ja) 2015-09-10
US20170128422A1 (en) 2017-05-11
HK1198476A1 (zh) 2015-05-08
RU2639145C2 (ru) 2017-12-20
CN103958480A (zh) 2014-07-30
EP2894151A4 (en) 2016-01-20
JP6262733B2 (ja) 2018-01-17
DK2894151T3 (da) 2021-01-11
KR20150047591A (ko) 2015-05-04
MX368844B (es) 2019-10-16
RS61242B1 (sr) 2021-01-29
AU2013312587A1 (en) 2015-03-19
MX2015002602A (es) 2015-06-10
KR102189940B1 (ko) 2020-12-14
LT2894151T (lt) 2021-09-10
RU2015110122A (ru) 2016-10-27

Similar Documents

Publication Publication Date Title
HK1198476A1 (zh) 咪唑啉類衍生物、其製備方法及其在醫藥上的應用
HRP20181172T1 (hr) Derivati pirazolpirimidina supstituirani na poziciji 4, te njihova uporaba u proizvodnji lijekova
HK1209599A1 (en) Products including capsules, uses and preparation thereof
EP2881395A4 (en) PIPERAZINOTRIZOLE COMPOUND, PROCESS FOR PREPARING THE SAME AND USE THEREOF IN THE PREPARATION OF MEDICAMENT
IL234628A0 (en) Imidazolyl-pyrimidines are converted into amino-indolyl and their use as drugs
ZA201404625B (en) Polycyclic derivatives, preparation method and medical uses thereof
HK1207065A1 (en) Nitrogenous heterocyclic derivatives and their application in drugs
HK1207075A1 (en) Glucopyranosyl derivatives and their uses in medicine
HK1222563A1 (zh) 藥物組合物、製備及其用途
IL243734B (en) History of oxoquinazolinyl-butanamide, their preparation and medicines containing them
HK1198833A1 (en) N-acylpeptide derivatives and their uses n-
EP2865666A4 (en) HEXAHYDROPENTALENE DERIVATIVES, METHOD OF MANUFACTURE AND USE IN MEDICINE
IL243223A0 (en) History of imidazole, their preparation and pharmaceutical preparations containing them
EP2805956A4 (en) GAMBOGIC ACID DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF
HK1211570A1 (en) Indene derivatives, their preparation and use as medicaments
HK1212968A1 (zh) 氨基環丁烷衍生物、其製備方法及其用作藥物的用途
EP2926811A4 (en) ARTEMISCULAR PHARMACEUTICAL COMPOSITION, MANUFACTURE AND USE
EP2844661A4 (en) FUSIONED HETEROCYCLE MORPHINANES, THEIR USE AND PREPARATION THEREOF
IL234614B (en) Pharmaceutical composition and preparation method thereof
IL284405A (en) Pharmaceutical composition, preparation and uses thereof